Lite Strategy, Inc. Amends 8-K Filing
Ticker: LITS · Form: 8-K/A · Filed: Nov 20, 2025 · CIK: 1262104
Sentiment: neutral
Topics: amendment, corporate-governance, officer-changes
TL;DR
Lite Strategy (formerly MEI Pharma) filed an 8-K/A on Nov 20, amending Nov 14 report on exec/director changes.
AI Summary
Lite Strategy, Inc. filed an amendment (8-K/A) on November 20, 2025, to a report originally dated November 14, 2025. The filing pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. The company, formerly known as MEI Pharma, Inc., is located in San Diego, California.
Why It Matters
This amendment provides updated information regarding changes in the company's board of directors and executive officers, which can impact corporate governance and strategic direction.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially those concerning executive and director changes, can signal internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- Lite Strategy, Inc. (company) — Registrant
- MEI Pharma, Inc. (company) — Former company name
- November 14, 2025 (date) — Date of earliest event reported
- November 20, 2025 (date) — Filing date
- San Diego, California (location) — Principal executive offices location
FAQ
What specific items are being amended in the 8-K filing?
The amendment pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What was the original report date that this 8-K/A amends?
The original report date was November 14, 2025.
When was this amendment filed with the SEC?
This amendment was filed on November 20, 2025.
What is the current name of the company filing this amendment?
The current name of the company is Lite Strategy, Inc.
What was Lite Strategy, Inc. formerly known as?
Lite Strategy, Inc. was formerly known as MEI Pharma, Inc.
Filing Stats: 761 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-11-20 17:29:48
Key Financial Figures
- $0.00000002 — nge on which registered Common Stock, $0.00000002 par value LITS The Nasdaq Stock Mar
- $2.02 — on Nasdaq on the date of grant and (b) $2.02 (which is the exercise price per share
- $1 — tock on Nasdaq on November 20, 2025 was $1.70, and the Replacement Options thus ha
Filing Documents
- lits-20251114.htm (8-K/A) — 45KB
- 0001193125-25-290059.txt ( ) — 152KB
- lits-20251114.xsd (EX-101.SCH) — 25KB
- lits-20251114_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LITE STRATEGY, INC. Date: November 20, 2025 By: /s/ Justin J. File Chief Executive Officer, Chief Financial Officer and Secretarty